Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Moves To Block Unichem Over Xeljanz Patent

This article was originally published in Scrip

Executive Summary

Pfizer has moved court against Unichem Laboratories seeking to block the Indian firm from allegedly infringing its patents concerning the rheumatoid arthritis therapy, tofacitinib (Xeljanz).

You may also be interested in...



Legal Wrangles: Foreign Firms Gaming The System In India?

Indian companies have cried foul over what they claim are "unethical" practices deployed by foreign firms in the legal arena, among others, to safeguard their "patent monopoly".

Asia Deal Watch: Astellas Looks To Next-Gen AAV Vectors Despite Gene Therapy Clinical Setbacks

Astellas inks agreement with Dyno Therapeutics for access to its CapsidMap platform for novel AAV vectors. Taiho takes option to Arcus TIGIT-targeted antibody candidates.

Supply Chain Crunch Meets Olympics Shutdown: China, India Drug Makers Brace For Perfect Storm

To ensure the Beijing Winter Olympics is a smooth affair, the Chinese government has ordered partial or complete halts in industrial production in some provinces from late November until mid-March, disrupting an already fragile global pharma active ingredient supply chain. The emergence of the Omicron coronavirus variant is just adding to the complexities.

Topics

UsernamePublicRestriction

Register

SC064748

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel